X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with PLETHICO PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs PLETHICO PHARMA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. PLETHICO PHARMA FRESENIUS KABI ONCO./
PLETHICO PHARMA
 
P/E (TTM) x 22.1 -1.1 - View Chart
P/BV x 3.1 0.0 18,573.0% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 FRESENIUS KABI ONCO.   PLETHICO PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
PLETHICO PHARMA
Mar-14
FRESENIUS KABI ONCO./
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs176395 44.6%   
Low Rs7931 250.8%   
Sales per share (Unadj.) Rs37.7604.4 6.2%  
Earnings per share (Unadj.) Rs5.132.5 15.7%  
Cash flow per share (Unadj.) Rs6.751.3 13.1%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.5473.6 9.0%  
Shares outstanding (eoy) m158.2334.08 464.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.4 957.7%   
Avg P/E ratio x25.06.6 380.8%  
P/CF ratio (eoy) x18.94.2 455.9%  
Price / Book Value ratio x3.00.5 664.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,1357,262 277.2%   
No. of employees `0001.2NA-   
Total wages/salary Rs m7031,596 44.1%   
Avg. sales/employee Rs Th5,176.2NM-  
Avg. wages/employee Rs Th610.4NM-  
Avg. net profit/employee Rs Th699.6NM-  
INCOME DATA
Net Sales Rs m5,96320,598 28.9%  
Other income Rs m18386 4.7%   
Total revenues Rs m5,98120,984 28.5%   
Gross profit Rs m1,4302,818 50.8%  
Depreciation Rs m258642 40.2%   
Interest Rs m-261,593 -1.6%   
Profit before tax Rs m1,216969 125.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342-138 -247.3%   
Profit after tax Rs m8061,107 72.8%  
Gross profit margin %24.013.7 175.3%  
Effective tax rate %28.1-14.3 -196.9%   
Net profit margin %13.55.4 251.5%  
BALANCE SHEET DATA
Current assets Rs m5,10218,877 27.0%   
Current liabilities Rs m2,38511,896 20.1%   
Net working cap to sales %45.633.9 134.4%  
Current ratio x2.11.6 134.8%  
Inventory Days Days15036 417.5%  
Debtors Days Days113198 57.3%  
Net fixed assets Rs m5,1489,861 52.2%   
Share capital Rs m158341 46.4%   
"Free" reserves Rs m6,55612,331 53.2%   
Net worth Rs m6,73216,139 41.7%   
Long term debt Rs m9524,706 20.2%   
Total assets Rs m10,38833,146 31.3%  
Interest coverage x-45.81.6 -2,847.0%   
Debt to equity ratio x0.10.3 48.5%  
Sales to assets ratio x0.60.6 92.4%   
Return on assets %7.58.1 92.2%  
Return on equity %12.06.9 174.5%  
Return on capital %14.612.3 118.8%  
Exports to sales %74.521.4 348.4%   
Imports to sales %24.815.2 162.7%   
Exports (fob) Rs m4,4414,402 100.9%   
Imports (cif) Rs m1,4773,136 47.1%   
Fx inflow Rs m5,2984,402 120.3%   
Fx outflow Rs m1,7723,184 55.7%   
Net fx Rs m3,5251,219 289.3%   
CASH FLOW
From Operations Rs m1,2742,437 52.3%  
From Investments Rs m-1,204-6,265 19.2%  
From Financial Activity Rs m-1962,490 -7.9%  
Net Cashflow Rs m-126-1,337 9.4%  

Share Holding

Indian Promoters % 0.0 82.7 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 4.3 7.0%  
FIIs % 9.6 5.5 174.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 7.5 121.3%  
Shareholders   42,599 10,665 399.4%  
Pledged promoter(s) holding % 0.0 85.7 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   PFIZER  ABBOTT INDIA  PANACEA BIOTECH  WYETH LTD  GSK PHARMA  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Firm; Healthcare & Metal Stocks Gain(09:30 am)

Asian stocks are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.17% while the Hang Seng is up 0.95%. The Nikkei 225 is trading up by 0.4%.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS